But BMY is currently a leader in investigating this neoadjuvant strategy in lung cancer, and it has real potential to make a big difference, in a similar way that AstraZeneca ( AZN ) did with the PACIFIC trial. By taking the fight to earlier stages of lung cancer, BMY stands to gain major advantages in the market. So this could be the beginning of a big move for it. I still think this crush on BMY is overblown, and I won't be surprised if it pulls off a fairly big turnaround. News: CLDX announced that the top-line data from its phase 2 METRIC study in triple-negative breast cancer failed to deliver. This trial randomized patients to receive the antibody-drug conjugate glembatumumab vedotin or capecitabine for tumors overexpressing the marker targeted by the conjugate, gpNMB. The study failed to meet the primary endpoint of progression-free survival. And the company has announced that development of glembatumumab vedotin will be suspended across all indications. Looking forward: Very bad news, and rather surprising, given the early signs of efficacy that have been observed in the past. It's also a major shock to the system for CLDX, which has now had several high-profile drug failures. While it's possible the company could recover with its remaining pipeline, that's what we said about rindopepimut's failure, and here we are.acupuncture Clifton
For the original version including any supplementary images or video, visit https://seekingalpha.com/article/4163943-3-things-biotech-april-18-bristol-plows-ahead-celldex-flops-alkermes-gets-surprise
But bee venom therapies are often linked to adverse reactions, and there is little published research to support their safety and effectiveness, according to the new case report. For people who are sensitive to bee venom, the venom's compounds can trigger allergic reactions that range from mild to severe. In extreme cases, they cause anaphylaxis , an allergic reaction that can strike within moments after exposure to the allergen, and can be life-threatening. During anaphylaxis, the body floods with chemicals that induce a state of shock; blood pressure drops and the tongue and throat can swell, making it difficult to breathe, according to the Mayo Clinic . The hormone epinephrine , also known as adrenaline, can ease anaphylaxis symptoms, but the apitherapy clinic in Spain did not have any on hand. And though the unconscious woman was given epinephrine once medical help arrived, the ambulance didn't show up until about 30 minutes after the clinic workers placed the call, according to the case report. Curiously, this wasn't the woman's first visit to the apitherapy clinic; in fact, she had been visiting the clinic and receiving bee acupuncture every four weeks for the past two years, with no adverse effects reported. What likely happened is that she developed a sensitivity to honeybee venom over the course of her treatment, "and the last sting was the clinically relevant one that was fatal," Dr. Andrew Murphy, an allergist with the Asthma Allergy and Sinus Center in Downingtown, Pennsylvania, told Live Science in an email. In other words, people can develop a sensitivity to allergens such as bee venom through regular exposure.
For the original version including any supplementary images or video, visit https://www.livescience.com/62063-bee-acupuncture-death.html